Literature DB >> 26911153

Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS).

D Lamichhane1, A Weinstein2.   

Abstract

Complement activation is a key feature of systemic lupus erythematosus (SLE). Detection of cell-bound complement activation products (CB-CAPS) occurs more frequently than serum hypocomplementemia in definite lupus. We describe a patient with normocomplementemic probable SLE who did not fulfill ACR classification criteria for lupus, but the diagnosis was supported by the presence of CB-CAPS.
© The Author(s) 2016.

Entities:  

Keywords:  Systemic lupus erythematosus (SLE); cell-bound complement activation products (CB-CAPS); complement; neuromyelitis optica (NMO)

Mesh：

Substances：

Year:  2016        PMID： 26911153     DOI： 10.1177/0961203316635287

Source DB:  PubMed          Journal:  Lupus        ISSN： 0961-2033            Impact factor:   2.911


  2 in total

1.  Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.

Authors:  Rosalind Ramsey-Goldman; Roberta Vezza Alexander; Elena M Massarotti; Daniel J Wallace; Sonali Narain; Cristina Arriens; Christopher E Collins; Amit Saxena; Chaim Putterman; Kenneth C Kalunian; Tyler O'Malley; Thierry Dervieux; Arthur Weinstein
Journal:  Arthritis Rheumatol       Date:  2019-11-25       Impact factor: 10.995

Review 2.  Cell-bound complement activation products in SLE.

Authors:  Rosalind Ramsey-Goldman; Jian Li; Thierry Dervieux; Roberta Vezza Alexander
Journal:  Lupus Sci Med       Date:  2017-08-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.